Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
February 08, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Participation in Upcoming Investor Conferences
January 31, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
January 04, 2024 06:15 ET
|
Zymeworks Inc.
Company well-positioned for further progress and broadening of R&D pipelineCash resources of approximately $455 million as of December 31, 2023 (unaudited)Expected cash runway, including proceeds...
Zymeworks Announces Additional Leadership Appointments
January 04, 2024 06:00 ET
|
Zymeworks Inc.
Dr. Jeffrey Smith named Executive Vice President and Chief Medical OfficerDr. John Fann promoted to Senior VP, Process SciencesSeven new Vice Presidents appointed, underscoring commitment to...
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
December 26, 2023 08:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today...
Zymeworks Added to Nasdaq Biotechnology Index
December 15, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...
Zymeworks Announces Participation in Upcoming Investor Conference
November 30, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...
Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 07, 2023 16:05 ET
|
Zymeworks Inc.
Net loss for the first nine months of 2023 decreased by 44% as compared to the same period in 2022Cash resources of $390.2 million as of September 30, 2023 expected to fund planned operations through...
Zymeworks Announces Participation in Upcoming Investor Conferences
November 01, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...
Zymeworks To Host Third Quarter 2023 Results Conference Call
October 17, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...